Searchable abstracts of presentations at key conferences in endocrinology

ea0089c2 | Clinical – Chemo/SSA/Biologics | NANETS2022

Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Neoplasms

Hunter, MD Lindsay A , Whisenant, MD Jonathan , Weldon Gilcrease, MD G.

Background: High-grade neuroendocrine neoplasms (HG-NENs) are a heterogenous and biologically aggressive rare subset of NENs. Few therapeutic options are available to metastatic HG-NENs. To date, first line treatment is platinum- or temozolomide-based chemotherapy which provide modest benefits in overall survival (OS) and progression free survival (PFS). Given the promising activity of immunotherapy across several cancer types, our center initiated a phase II trial of pembroli...

ea0089p8 | Population Science | NANETS2022

Multivisceral Surgical Resection of Locally Advanced Pancreatic Neuroendocrine Tumor is Associated with a Survival Benefit

Hernandez, MD Matthew C. , Sullivan, MD Kevin M. , Melstrom, MD Laleh G. , Fong, MD Yuman , MD Gagandeep Singh

Background: In patients with locally advanced pancreatic neuroendocrine tumors (PNET), surgical resection is associated with improved survival. There is a paucity of data whether there is a benefit for multivisceral resection for locally advanced PNET compared to pancreatectomy alone. This study investigated the association of surgical resection on overall survival comparing pancreas specific and multivisceral resection for PNET.Methods: The Surveillance...

ea0089c33 | Clinical – Surgery/Applied Pathology | NANETS2022

High-Grade Pancreatic Neuroendocrine Neoplasms: Interobserver Diagnostic Accuracy and Relationship with Clinicopathological and Molecular Characteristics

Taherian, MD Mehran , Waters, MD Rebecca , Foo, MD Wai Chin , Maru, MD Dipen , Abraham, MD Susan C. , Rashid, MBBS, PhD Asif , Wang, MD, PhD Huamin , Wei, MD Dongguang , Taggart, MD Melissa W. , Chatterjee, MD Deyali

Background: The pathogenesis, biologic behavior, and treatment of well-differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC) are different. The diagnosis relies on multiple factors, but pathologic assessment is crucial. Based on currently available diagnostic criteria, the distinction between NET G3 and NEC are made on morphologic assessment, without taking Ki-67 proliferative index into consideration. This study looks at the conc...

ea0013p251 | Neuroendocrinology and behaviour (including pituitary) | SFEBES2007

Upward resetting of osmostat – rare or under diagnosed?

Chowdhury Sharmistha Roy , Evans PMS , Penney MD , Page MD

Two patients presented to us with polyuria and polydipsia.Case 1– A 34 year old gentleman was referred with polyuria, polydipsia, diffuse headaches and poor sleep. Initial plasma and urine osmolality were 306 and 272 milliosmol/kg respectively. Water deprivation test demonstrated normal concentrating ability. Starting urinary osmolality was 788 milliosmol/kg, rising to 877 milliosmol/kg. MRI pituitary was normal. Hypertonic saline infusion test prod...

ea0089c7 | Clinical – Chemo/SSA/Biologics | NANETS2022

Risk of Myelodysplastic Syndrome/Acute Leukemia with Sequential Capecitabine/Temozolomide and 177Lu-Dotatate

MPH Taymeyah Al-Toubah , MD Eleonora Pelle , MD Jonathan Strosberg

Background: The treatment landscape for neuroendocrine tumors includes alkylating-agent chemotherapy and peptide receptor radiotherapy (PRRT) with 177Lu-Dotatate. The risk of MDS/AML associated with 177Lu-Dotatate is approximately 2-3%. Several small prior studies have suggested substantially higher rates of MDS/AML (approximately 10%) in patients who have also received alkylating agent chemotherapy with streptozocin or temozolomide, either combined with PRRT or sequentially. ...

ea0089c37 | Clinical – Surgery/Applied Pathology | NANETS2022

Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?

C. Borbon, MD Luis , G. Tran, MD Catherine , K. Sherman, MD Scott , Hien Ear, PhD Po , Chandrasekharan, MD Chandrikha , M. Bellizzi, MD Andrew , S. Dillon, MD Joseph , M. O'Dorisio, MD Thomas , R. Howe, MD James

Background: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are aggressive tumors with poor survival outcomes for which medical management is usually recommended. This study sought to evaluate outcomes of surgically treated G3 GEP-NEN patients.Methods: A single-institutional prospective NEN database was reviewed. Patients with G3 GEP-NENs based on World Health Organization (WHO) 2019 definitions included well-differentiated neur...

ea0089c38 | Clinical – Surgery/Applied Pathology | NANETS2022

Increased Incidence, Prevalence, and Surgical Management of Enteropancreatic Neuroendocrine Tumors Is Associated with Improvements in Survival - A Contemporary Analysis

Concors, MD Seth J , Tzeng, MD Ching-Wei D , Ikoma MD Naruhiko , Kim MD Michael , Cao, MD Hop Tran , Lee, MD Jeffery E , Katz, MD Matthew HG , Maxwell, MD, MBA Jessica E

Background: Neuroendocrine tumors (NETs) are increasing in incidence and prevalence. Small intestine, rectum, pancreas and appendix are the most common enteric sites of NETs, and when identified early, surgical resection can be curative. We hypothesized that observed increases in incidence and prevalence of NETs are primarily driven by earlier detection of loco-regional tumors. In turn, increases in incidence of early-stage tumors is associated with increases in resection and ...

ea0089o1 | Other | NANETS2022

Efficacy and Toxicity of Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Tyrosine Kinase Inhibitors (TKIs) in Neuroendocrine Tumors (NETs) – A Systematic Review and Meta-Analysis

Das, MD, MSCI Satya , Phillips, MSPH Sharon , M Lebeck Lee, MD Cody , Agarwal, MD, MSCI Rajiv , Bergsland, MD Emily , Strosberg, MD Jonathan , A. Chan, MD, MPH Jennifer , LaFerriere, MLIS Heather , A. Ramirez, DO Robert , Berlin, MD Jordan , Arvind Dasari, MD, MS and

Background: Although anti-VEGF RTKIs have been tested in patients with NETs over the last 2 decades, no study to date has benchmarked efficacy and toxicity of these drugs in this patient population.Methods: A literature search was performed to identify all phase II and phase III studies of anti-VEGF RTKIs in patients with NETs published between January 1, 2000 – July 31, 2021. Major trial databases (e.g. Medline, EMBASE, Cumulative Index of Nursing ...

ea0089o2 | Other | NANETS2022

The Association Between Patient-Reported Symptom Burden and Urgent Healthcare Use in Patients Diagnosed with Neuroendocrine Tumors

Duncan, MD, MPH Katrina , Eskander, MD, ScM Antoine , Sutradhar, PhD Rinku , Noel, MD, PhD Christopher , Barabash, MSC Victoria , Coburn, MD, MPH Natalie , Law, MD, MPH Calvin , Singh, MD, MPH Simron , Myrehaug, MD Sten , Chan, MPH Wing , Hallet, MD, MSc Julie

Background: Patients with neuroendocrine tumors (NETs) have high burden of symptoms that persists over years after diagnosis. Patient-reported outcomes (PROs) are routinely screened for in oncology practice but seldomly used to trigger interventions. Further information about how PROs are linked to outcomes is necessary to improve their use for symptom management for NETs. We examined the association between PROs symptom burden and urgent healthcare use after NET diagnosis.</p...

ea0089o7 | Other | NANETS2022

Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumor Patients

Hunter, MD Lindsay A , Soares, MD, PhD Heloisa P.

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a clinically heterogenous group. Determining the appropriate selection of therapy and optimal monitoring can be difficult due to their diverse behavior. Furthermore, monitoring or surveillance typically consist of frequent imaging, potentially over decades. Circulating tumor DNA (ctDNA) has shown promise as a minimally invasive approach to disease monitoring and treatment response assessment in a variety o...